개 백신 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 부문, 백신 유형별, 질환 유형별, 면역 기간별, 투여 경로별, 지역별, 경쟁(2020-2030년)

Global Dog Vaccines Market was valued at USD 1.86 Billion in 2024 and is expected to reach USD 2.69 Billion in the forecast period with a CAGR of 6.32% through 2030. The global dog vaccines market is experiencing significant growth as pet ownership continues to rise and awareness about animal health intensifies. Pet owners are becoming increasingly conscious of the importance of preventative healthcare for their dogs, driving demand for vaccines that prevent a variety of infectious diseases. As veterinary care standards improve and pet health knowledge increases, dog vaccines have become a vital aspect of responsible pet ownership. The availability of more effective and targeted vaccines has further bolstered market growth, as pet owners seek to ensure the well-being of their pets through vaccination programs.

One of the key drivers of this market is the growing number of pet adoptions worldwide. With more people choosing to welcome dogs into their homes, the need for routine vaccinations to protect pets from diseases such as rabies, distemper, parvovirus, and leptospirosis is on the rise. In addition, advances in vaccine technology have led to the development of more effective vaccines with fewer side effects, thus encouraging greater adoption among pet owners. As veterinary clinics and animal healthcare services become more accessible and equipped with advanced diagnostic and treatment technologies, the demand for vaccines continues to rise.

However, there are challenges within the dog vaccines market that must be addressed to sustain growth. The high cost of certain vaccines and the limited availability of vaccines in some regions can hinder access to preventative care for many pet owners. Moreover, concerns regarding vaccine-related side effects and the growing popularity of alternative medicine for pets could impact market expansion. Despite these challenges, the growing trend of pet insurance and government regulations encouraging vaccination programs present opportunities for further growth. As pet owners invest more in their pets' health, the demand for dog vaccines is expected to continue rising, driven by the need for preventive measures to ensure the longevity and health of dogs.

Key Market Drivers

Rising Pet Ownership

The surge in pet ownership worldwide has significantly influenced the global dog vaccines market. As more households welcome dogs as companions, the demand for comprehensive healthcare, including vaccinations, has escalated. In the United States, for instance, approximately 86.9 million households owned a pet in 2023, accounting for 66% of households. Among these, 65.1 million households had at least one dog, highlighting the substantial canine population.

This increase in pet ownership has led to a higher demand for veterinary services, including vaccinations. Pet owners are more inclined to invest in their pets' health, recognizing the importance of preventive care to ensure their dogs lead healthy and fulfilling lives. The growing number of pet owners has also contributed to the expansion of the pet healthcare market. This expansion is driven by the increasing humanization of pets, where owners view their pets as family members, leading to higher spending on pet-related products and services, including vaccines. As pet ownership continues to rise, the demand for dog vaccines is expected to grow correspondingly, presenting opportunities for market expansion and innovation in veterinary care.

Advancements in Vaccine Technology

Advancements in vaccine technology have been a critical driver of growth in the global dog vaccines market. The development of more effective and safer vaccines has significantly improved the ability to prevent a wide range of infectious diseases in dogs. New technologies such as recombinant DNA technology, adjuvant improvements, and mRNA vaccines are making it possible to create vaccines that offer enhanced protection while reducing the risk of side effects. These innovations ensure that dogs are better protected against diseases like rabies, distemper, parvovirus, and leptospirosis, contributing to improved pet health worldwide.

The rise of combination vaccines is another important advancement. Combination vaccines, which provide protection against several diseases with a single injection, are becoming increasingly popular. These vaccines simplify the vaccination process for pet owners by reducing the number of vet visits and injections required, making it easier to ensure that dogs are fully vaccinated. The development of these combination vaccines also makes vaccination more cost-effective, which further encourages adoption among pet owners.

Recent advancements also include the development of vaccines with extended protection periods. This means fewer booster shots are required over the life of the dog, which improves convenience for both pet owners and veterinarians. Improved stability of vaccines, which allows for easier storage and longer shelf life, has also expanded the accessibility of vaccines, particularly in remote areas where veterinary services may be limited.

These technological strides in vaccine development have not only increased the safety and efficacy of vaccines but also fostered greater confidence in pet vaccination programs, leading to higher vaccination rates. As these innovations continue, the global dog vaccines market is expected to experience sustained growth, benefiting from more accessible, efficient, and effective vaccination solutions for pet owners.

Growth of Veterinary Healthcare Infrastructure

The growth of veterinary healthcare infrastructure is a key driver for the expansion of the global dog vaccines market. As pet ownership continues to rise globally, there is a corresponding increase in demand for veterinary services, including vaccinations. The accessibility and quality of veterinary care have significantly improved in recent years, leading to higher vaccination rates among pets. This growth in infrastructure is evident through the establishment of more veterinary clinics and animal hospitals, especially in urban areas, which cater to the growing pet population. As of recent reports, there has been a notable surge in the number of veterinary professionals and clinics offering a wider range of services, from routine check-ups to specialized treatments.

The increasing number of pet owners worldwide has been a driving force behind the expansion of veterinary healthcare facilities. For example, in countries such as the United States, over 90 million households now own pets, which has created a larger market for pet healthcare services. This surge in pet ownership has prompted veterinary clinics to expand their operations and offer more comprehensive healthcare solutions. At the same time, advancements in veterinary care, such as improved diagnostic tools and treatment options, have made it easier for clinics to provide effective care, including timely vaccinations for pets.

Government initiatives also play a crucial role in supporting the growth of veterinary healthcare infrastructure. Several countries have implemented programs to promote animal health and strengthen the veterinary workforce, including funding for veterinary clinics and training for veterinary professionals. This, in turn, ensures greater access to vaccines for pets and contributes to higher vaccination rates. As more pet owners seek professional care for their animals, the demand for dog vaccines continues to rise, further fueling the market's growth. Improved infrastructure and government support are creating a favorable environment for increased pet vaccination, thereby driving the expansion of the dog vaccines market.

Key Market Challenges

High Cost of Vaccination

One of the major challenges facing the global dog vaccines market is the high cost of vaccination, which can limit access to essential preventive healthcare for pets, particularly in lower-income regions. The price of vaccines varies depending on the type of vaccine, the brand, and the country in which they are administered. Vaccination costs are influenced by several factors, including the research and development expenses involved in creating new vaccines, regulatory fees, and distribution costs. For example, combination vaccines, which provide protection against multiple diseases in one dose, can be more expensive than single vaccines, further escalating the overall cost for pet owners.

In addition to the direct costs of vaccines, pet owners may incur additional charges for veterinary consultations and health assessments to determine which vaccines are needed for their dogs. This makes the vaccination process financially challenging for individuals, especially in regions where veterinary care is not subsidized or where pet healthcare is not covered by insurance. According to a report from the American Kennel Club, a basic vaccination package for a dog in the U.S. can cost anywhere from USD 75 to USD 150, depending on the vaccines included. More advanced vaccines or those for rare diseases may cost even more. These costs can be a significant burden for pet owners in developing countries or low-income households, potentially resulting in lower vaccination rates.

For reference, the U.S. Centers for Disease Control and Prevention (CDC) provides cost data on rabies vaccination for pets, noting that rabies shots alone can cost between USD 15 and USD 30. However, pet owners are often required to cover the additional costs of vet visits and consultations, which can push the total cost of vaccination higher. The high cost of dog vaccines can hinder market growth by limiting access to vaccines in economically disadvantaged regions.

Vaccine-Related Side Effects

Vaccine-related side effects remain a significant challenge in the global dog vaccines market, despite the general safety of vaccines. While most vaccines are well-tolerated, some dogs may experience mild to severe reactions, which can deter pet owners from vaccinating their dogs. Common mild side effects include fever, lethargy, swelling at the injection site, or temporary loss of appetite, which typically subside within a few days. However, more severe reactions, such as anaphylaxis, allergic reactions, or autoimmune disorders, although rare, pose a higher risk. These adverse effects can lead to concern among pet owners, who may then become hesitant about vaccinating their pets in the future. This reluctance to vaccinate is especially problematic in areas with low vaccine coverage, where it can lead to increased vulnerability to preventable diseases.

The fear of potential side effects often arises from the lack of understanding among pet owners about the nature of these reactions and the real risks involved. Misconceptions about the frequency and severity of side effects contribute to vaccine hesitancy, as many pet owners may not be aware that the benefits of vaccination far outweigh the risks. Additionally, some alternative treatments and non-traditional medicine practices that claim to boost pet health without vaccines are gaining popularity, further exacerbating concerns about vaccination. This shift away from conventional vaccination practices, especially among pet owners who are more focused on natural or holistic approaches, presents a challenge to the overall success of vaccination campaigns. Veterinary professionals play a crucial role in educating pet owners about the safety and importance of vaccinations to combat these concerns and ensure that dogs remain protected from preventable diseases.

Key Market Trends

Personalized Vaccines and Tailored Approaches

Personalized vaccines and tailored approaches are becoming a significant trend in the global dog vaccines market as pet owners and veterinary professionals seek more precise and effective healthcare solutions. This trend involves customizing vaccination plans based on a dog's specific characteristics, such as breed, age, health status, environmental factors, and genetic predispositions. Veterinarians are increasingly using this personalized approach to better understand how different dogs respond to vaccines, ensuring that the vaccines administered are the most suitable for the individual animal. For example, certain breeds or dogs with pre-existing health conditions may be more susceptible to specific diseases, while others may require a different vaccination schedule or a modified vaccine dosage to avoid side effects.

Tailored vaccination plans also consider the dog's lifestyle and environment, which can impact its risk of exposure to infectious diseases. Dogs that live in areas with higher incidences of certain diseases or those that are exposed to other animals may need targeted vaccines for specific pathogens, while dogs in low-risk environments may need fewer vaccinations. Genetic testing is increasingly being used to understand a dog's immune system and its ability to respond to certain vaccines. This trend is driven by growing knowledge about animal genetics and immune responses, as well as advances in veterinary medicine.

Personalized vaccines not only improve the effectiveness of immunization but also help mitigate potential risks associated with over-vaccination. By tailoring vaccines to the specific needs of each dog, this approach reduces unnecessary vaccine administration, which can lower the risk of adverse reactions. As pet owners become more aware of the benefits of personalized care and as veterinary technology advances, the demand for tailored vaccination plans is expected to grow, shaping the future of pet healthcare.

Growing Focus on Combination Vaccines

The growing focus on combination vaccines in the global dog vaccines market is driven by the increasing demand for convenience, cost-effectiveness, and efficient healthcare solutions for pets. Combination vaccines, which protect dogs against multiple diseases with a single injection, have become a preferred option for pet owners and veterinarians alike. These vaccines reduce the number of visits to veterinary clinics, making them particularly appealing to pet owners with busy schedules or those in areas with limited access to veterinary services. By consolidating multiple vaccines into one, pet owners can ensure their dogs are protected from a variety of diseases while minimizing the time and cost associated with administering individual vaccines.

Combination vaccines are also beneficial from a health perspective, as they help maintain a streamlined vaccination schedule. The reduced number of injections lowers the risk of vaccine-related side effects, which may be a concern for some pet owners. This trend is particularly important as veterinary practices aim to enhance both the safety and efficacy of vaccination programs. The ability to target a wide range of diseases, such as distemper, parvovirus, and hepatitis, in one vaccine has made these products an essential part of routine pet healthcare, particularly for younger dogs who need to receive multiple vaccinations early in life.

As vaccine manufacturers continue to innovate, the development of new and improved combination vaccines is expected to expand, offering protection against an even broader range of diseases. This growth aligns with the rising trend of preventive healthcare for pets, as owners become more focused on proactive measures to safeguard their pets' health. The increasing adoption of combination vaccines is reshaping the dog vaccines market, offering both practical and economic benefits for pet owners while maintaining high levels of protection against infectious diseases.

Segmental Insights

Vaccine Type Insights

Based on the Vaccine Type, Modified/ Attenuated Live emerged as the dominant segment in the Global Dog Vaccines Market in 2024. This is primarily due to their proven efficacy and widespread use. These vaccines contain live pathogens that have been weakened to the point where they cannot cause disease but still stimulate a strong immune response in the animal. This type of vaccine has been widely used in veterinary medicine for many years because it provides long-lasting immunity and can protect dogs against several infectious diseases with a single dose. Modified/Attenuated Live vaccines are particularly effective for diseases such as distemper, parvovirus, and rabies, where robust immunity is essential to prevent the spread of potentially fatal conditions.

Additionally, the cost-effectiveness of Modified/Attenuated Live vaccines makes them a popular choice among veterinarians and pet owners. They often require fewer doses compared to inactivated vaccines, reducing the overall cost of vaccination programs. The ease of administration and availability of combination vaccines, which combine protection against multiple diseases in one shot, also contribute to the widespread adoption of Modified/Attenuated Live vaccines. Their ability to elicit strong, lasting immune responses, combined with practical benefits, ensures that this vaccine type continues to dominate the global dog vaccines market.

Disease Type Insights

Based on the Disease Type, Canine Infectious Respiratory Disease Complex (CIRDC) emerged as the dominant segment in the Global Dog Vaccines Market in 2024. This is driven by the high prevalence and significant impact of respiratory diseases in dogs. CIRDC, commonly known as kennel cough, is a highly contagious disease complex that affects the upper respiratory tract of dogs. It is caused by a combination of viruses and bacteria, including Bordetella bronchiseptica, parainfluenza virus, and canine adenovirus. These diseases are particularly common in environments where dogs are in close contact with each other, such as kennels, shelters, and dog parks. The high incidence of CIRDC, combined with its rapid transmission, has led to increased demand for vaccines that prevent this disease complex. Vaccines for CIRDC are essential in safeguarding the health of dogs, especially those in high-risk environments. The availability of vaccines that protect against multiple pathogens in the CIRDC spectrum, such as combination vaccines, has further driven the market's growth.

Regional Insights

North America emerged as the dominant region in the Global Dog Vaccines Market in 2024. This is largely due to several key factors, including a high level of pet ownership, advanced veterinary healthcare infrastructure, and strong regulatory frameworks. The United States and Canada have some of the highest rates of pet ownership globally, with millions of households owning dogs as pets. This large pet population drives the demand for preventive healthcare, including vaccines, to ensure the well-being of pets and prevent the spread of infectious diseases. Moreover, North America benefits from well-established veterinary clinics and hospitals equipped with the latest technologies for administering vaccines and providing comprehensive care. The region's advanced healthcare infrastructure, along with a strong network of veterinary professionals, ensures that pets receive timely and effective vaccinations. Additionally, pet owners in North America are increasingly focused on the health and longevity of their pets, which contributes to the widespread adoption of vaccination programs.

The regulatory environment in North America also plays a crucial role in promoting vaccination, as governments in the region have strict vaccination guidelines for pets, particularly for diseases like rabies. These regulations, combined with high awareness of pet health, have solidified North America's position as the dominant region in the global dog vaccines market.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

Report Scope:

In this report, the Global Dog Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dog Vaccines Market, By Vaccine Type:

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Dog Vaccines Market, By Disease Type:

• Canine Distemper
• Canine Infectious Respiratory Disease Complex (CIRDC)
• Canine Parvovirosis/ Parvovirus Disease
• Canine Leptospirosis
• Canine Lyme Disease
• Infectious Canine Hepatitis
• Canine Rabies
• Others

Dog Vaccines Market, By Duration of Immunity:

• 1 Year
• 3 Year
• Others

Dog Vaccines Market, By Route of Administration:

• Injectables
• Intranasal
• Oral

Dog Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dog Vaccines Market.

Available Customizations:

Global Dog Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Dog Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.2. By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex (CIRDC), Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Others)
  • 5.2.3. By Duration of Immunity (1 Year, 3 Year, Others)
  • 5.2.4. By Route of Administration (Injectables, Intranasal, Oral)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Dog Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Duration of Immunity
  • 6.2.4. By Route of Administration
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dog Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Duration of Immunity
      • 6.3.1.2.4. By Route of Administration
  • 6.3.2. Mexico Dog Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Duration of Immunity
      • 6.3.2.2.4. By Route of Administration
  • 6.3.3. Canada Dog Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Duration of Immunity
      • 6.3.3.2.4. By Route of Administration

7. Europe Dog Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Duration of Immunity
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Dog Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Duration of Immunity
      • 7.3.1.2.4. By Route of Administration
  • 7.3.2. Germany Dog Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Duration of Immunity
      • 7.3.2.2.4. By Route of Administration
  • 7.3.3. United Kingdom Dog Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Duration of Immunity
      • 7.3.3.2.4. By Route of Administration
  • 7.3.4. Italy Dog Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Duration of Immunity
      • 7.3.4.2.4. By Route of Administration
  • 7.3.5. Spain Dog Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Duration of Immunity
      • 7.3.5.2.4. By Route of Administration

8. Asia-Pacific Dog Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Duration of Immunity
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Dog Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Duration of Immunity
      • 8.3.1.2.4. By Route of Administration
  • 8.3.2. India Dog Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Duration of Immunity
      • 8.3.2.2.4. By Route of Administration
  • 8.3.3. South Korea Dog Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Duration of Immunity
      • 8.3.3.2.4. By Route of Administration
  • 8.3.4. Japan Dog Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Duration of Immunity
      • 8.3.4.2.4. By Route of Administration
  • 8.3.5. Australia Dog Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Duration of Immunity
      • 8.3.5.2.4. By Route of Administration

9. South America Dog Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Duration of Immunity
  • 9.2.4. By Route of Administration
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dog Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Duration of Immunity
      • 9.3.1.2.4. By Route of Administration
  • 9.3.2. Argentina Dog Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Duration of Immunity
      • 9.3.2.2.4. By Route of Administration
  • 9.3.3. Colombia Dog Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Duration of Immunity
      • 9.3.3.2.4. By Route of Administration

10. Middle East and Africa Dog Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Duration of Immunity
  • 10.2.4. By Route of Administration
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dog Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Duration of Immunity
      • 10.3.1.2.4. By Route of Administration
  • 10.3.2. Saudi Arabia Dog Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Duration of Immunity
      • 10.3.2.2.4. By Route of Administration
  • 10.3.3. UAE Dog Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Duration of Immunity
      • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Bioveta a.s
• 14.3. Hester Biosciences Limited
• 14.4. Boehringer Ingelheim International GmbH
• 14.5. Brilliant Bio Pharma Private Limited
• 14.6. Heska Corporation
• 14.7. Merck & Co., Inc.
• 14.8. Virbac S.A.
• 14.9. Zendal Group
• 14.10. Elanco Animal Health Incorporated

15. Strategic Recommendations

16. About Us & Disclaimer